Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Gilead Sciences is terminating Ambrisentan Phase III ongoing clinical trial, investigating patients with idiopathic pulmonary fibrosis (IPF), due to lack of efficacy.
Subscribe to our email newsletter
Ambrisentan is a non-sulfonamide, propanoic acid-class, endothelin receptor antagonist that is selective for the endothelin type-A (ETA) receptor.
Gilead Sciences’ decision is based on the interim analysis of unblinded efficacy and safety data by the study’s Data Monitoring Committee (DMC) and review of those data by Gilead, which did not show evidence of a treatment benefit in the group of patients randomized to receive Ambrisentan.
The company is reviewing the data and said that it will communicate the full results of this analysis to the medical community when they are available.